【와티비커뮤니티-WATVcommunity】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 스포츠뉴스 : 안구정화 놀이터홍보 놀이터후기공유 피해사례공유

로그인

채팅

글쓰기

[IT뉴스]Huons to Present Preclinical Data on Fibrostenotic Crohn’s Disease at UEG Week 2026

온카뱅크관리자

2026-10-30 08:57:26

TG2 Inhibition Shown to Reduce ECM Cross-Linking and Intestinal Fibrosis Accelerating Development of First-in-Class Drug Candidate HUC1A-626 
 <div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
 <section dmcf-sid="1PLqxpDgOB">
 [Kim Sungjin, Edaily Reporter] Huons has disclosed preclinical research results of its Crohn’s disease drug candidate at an international congress.
 Huons announced on the 20th that it presented preclinical research results for 'HUC1A-626', a selective TG2 inhibitor, via a poster presentation at the annual congress of the 'UEG Week 2026' (United European Gastroenterology Week 2026), held in Barcelona, Spain, from October 17th to 20th (local time).
 'HUC1A-626' is a candidate molecule currently being developed by Huons for the treatment of fibrostenotic Crohn’s disease (FSCD).
 <figure class="figure_frm origin_fig" contents-hash="9df06d5525ea3e53bf8c7ac9467637502373cffe24eb200e8c86e115e9db0a41" dmcf-pid="0RN9dzsAEu" dmcf-ptype="figure">
 <img alt="Huons participated in 'UEG Week 2026', the annual congress of the United European Gastroenterology held in Barcelona, Spain, October 17-20 (local time). In the photo, Huons’ researchers are presenting poster findings on the preclinical research results of 'HUC1A-626', a treatment candidate for fibrostenotic Crohn’s disease.(image=Huons.)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202610/30/Edaily/20261030084719209rjoz.png" data-org-width="567" dmcf-mid="5FcfnbCEOb" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202610/30/Edaily/20261030084719209rjoz.png" width="658">
 <figcaption class="txt_caption default_figure">
 Huons participated in 'UEG Week 2026', the annual congress of the United European Gastroenterology held in Barcelona, Spain, October 17-20 (local time). In the photo, Huons’ researchers are presenting poster findings on the preclinical research results of 'HUC1A-626', a treatment candidate for fibrostenotic Crohn’s disease.(image=Huons.)
 </figcaption>
 </figure>
 Intestinal fibrosis is a major complication appearing in approximately half of Crohn’s disease patients, characterized by the hardening and narrowing of the intestines. During chronic inflammatory processes, activated intestinal fibroblasts—the key cells responsible for tissue hardening—excessively accumulate extracellular matrix (ECM), which serves as structural support for cells. This leads to thickening of the intestinal wall and strictures that narrow the intestinal lumen. Crohn’s disease presenting in this form is referred to as FSCD.
 Currently available biological agents for Crohn’s disease are primarily focused on regulating inflammation, but failed to effectively suppress or reverse already progressed fibrotic lesions, highlighting the need for differentiated mechanism of action.
 Fibrotic intestinal tissue is not merely a residual trace left by inflammation. As the tissue becomes physically rigid, fibroblasts sense this biomechanical change and continuously secrete fibrotic factors, resulting in a vicious cycle that further exacerbates tissue fibrosis.
 Transglutaminase 2 (TG2) is an enzyme that abnormally cross-links ECM proteins and prevents the degradation of accumulated matrix, essentially acting as a glue that stiffens tissue. Huons’ researchers identified 'HUC1A-626', an oral TG2 inhibitor designed to act locally within the intestinal tract, and subsequently validated its anti-fibrotic effects across multiple cell and animal models.
 As a result, HUC1A-626 demonstrated high inhibitory potency and selectivity against TG2. In experiments using human colon-derived fibroblasts, TG2 inhibition confirmed multi-pathway anti-fibrotic effects. In animal models, fibrotic lesions and insoluble collagen content were reduced, showing distinct anti-fibrotic efficacy in both histological and quantitative analyses.
 These findings align with recent academic research trends suggesting that TG2 is more closely correlated with the degree of strictural fibrosis than with inflammatory responses. Based on these data, Huons plans to present a novel therapeutic strategy that targets the root cause of the disease, setting itself apart from conventional treatments.
 Kyung-mi Park, Vice President and Head of R&amp;D at Huons said, "Through this study, we confirmed that a TG2 inhibitor can simultaneously control ECM cross-linking and fibroblast activation, which are key drivers of intestinal fibrosis." She added, "We aim to develop HUC1A-626 as a first-in-class innovative drug that breaks the self-perpetuating cycle of fibrosis that persists even after inflammation subsides, providing a fundamental solution for patients with fibrostenotic Crohn’s disease."
 김성진 (jini@edaily.co.kr) 
 </section> 
 </div> 
 Copyright © 이데일리. 무단전재 및 재배포 금지.

27조 원전 따낸 ‘팀코리아’, 첫 삽도 뜨기 전 갈라섰다[Pick코노미] [아주초대석] 최영철 SGA솔루션즈 대표 "제로트러스트·N2SF 신사업 연 100% 성장 목표"

댓글 총 0개

업체홍보/구인 더보기

놀이터홍보 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기